Robert Mancini, PharmD, BCOP, FHOPA is the BMT Pharmacy Program Coordinator and PGY2 Oncology Residency Program Director at St. Luke's Cancer Institute (SLCI) and an Adjunct Clinical Instructor - Oncology at Idaho State University College of Pharmacy.

Robert has served in many roles as a hematology/oncology pharmacist. He helped start the Oral Chemotherapy Program at SLCI about 15 years ago and then went on to serve as pharmacist-in-charge at the Fruitland chemo infusion center. As part of an NCCCP grant through the SLCI, Robert helped establish an oncology supportive care clinic model.

In 2017, Robert became the first BMT Pharmacist and Program Coordinator within SLCI and helped establish the first and only allogeneic stem cell transplant program in Idaho. He went on to also help establish the first and only CAR-T program in the state in 2022.

Robert is the PGY2 Oncology Residency Program Director at SLCI and has overseen the development of more than 30 PGY2 Oncology Residents since 2012. He is an Adjunct Clinical Instructor who oversees the oncology therapeutics module at Idaho State University, including a special topics oncology elective he created in 2018.

Robert earned his PharmD from the University of California San Diego and completed a PGY1 Hospital Pharmacy Residency at St. Luke’s Health System and a PGY2 at St. Luke’s Mountain States Tumor Institute (now referred to as SLCI). He has been board certified in oncology since 2012. His research interests include BMT, cellular therapies, and oncology pharmacy education.